Cargando…

Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system

BACKGROUND: Amikacin inhale (BAY41-6551), a unique drug—device combination of a specially formulated drug solution and a pulmonary drug delivery system device (AMK-I) is currently under phase III study as an adjunctive therapy to IV antibiotics for the treatment of Gram-negative pneumonia in mechani...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghazi, Islam M., Grupper, Mordechai, Nicolau, David P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240302/ https://www.ncbi.nlm.nih.gov/pubmed/28095918 http://dx.doi.org/10.1186/s12941-017-0178-0

Ejemplares similares

High epithelial lining fluid concentrations of NKTR-061 (inhaled amikacin) twice daily achieved in pneumonic portions of lung
por: Chastre, J, et al.
Publicado: (2008)

Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa
por: Heffernan, Aaron J., et al.
Publicado: (2021)

Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens
por: Oesterreicher, Zoe, et al.
Publicado: (2017)

Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022)

In vitro efficiency of Amikacin Inhale, a novel drug-device delivery system
por: Kadrichu, N, et al.
Publicado: (2013)

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis
por: Kidogawa, Moe, et al.
Publicado: (2022)

The Effect of Clinical Concentrations of Meropenem (MEM), Ceftolozane/tazobactam (C/T), and Ceftazidime/avaibactam (CZA) on Time to Detection (TTD) and Growth of Pseudomonas aeruginosa (PSA) in bioMerieux BacT/ALERT(®)FA Plus Blood Culture (BC) Bottles
por: Grupper, Mordechai, et al.
Publicado: (2017)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Performance of amikacin inhale: impact of supplemental oxygen and device orientation
por: Kadrichu, N, et al.
Publicado: (2015)

1398. β-Lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) Based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model
por: Motos, Ana, et al.
Publicado: (2018)

Evaluating the efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in pediatric cystic fibrosis pulmonary exacerbation
por: Rakhshan, Amin, et al.
Publicado: (2023)

1397. Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Neutropenic (I−) vs. Immunocompetent (I+) Murine Models of Pneumonia
por: Kidd, James M, et al.
Publicado: (2018)

625. SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects
por: Rodvold, Keith A, et al.
Publicado: (2022)

1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β-Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2018)

Inhaled ceftazidime and amikacin versus inhaled colistin in the treatment of gram negative ventilator associated pneumonia
por: Nassar, YS, et al.
Publicado: (2015)

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
por: Motos, Ana, et al.
Publicado: (2023)

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients
por: Modongo, Chawangwa, et al.
Publicado: (2015)

Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery
por: Varshosaz, J., et al.
Publicado: (2013)

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints
por: Kuti, Joseph L, et al.
Publicado: (2018)

ELFE at CERN
por: Burkhardt, H
Publicado: (1999)

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats
por: Malinin, Vladimir, et al.
Publicado: (2016)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects
por: Van Wart, Scott A, et al.
Publicado: (2018)

The ELF3 transcription factor is associated with an epithelial phenotype and represses epithelial-mesenchymal transition
por: Subbalakshmi, Ayalur Raghu, et al.
Publicado: (2023)

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
por: Yagi, Kazuma, et al.
Publicado: (2017)

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
por: Kim, Bo-Guen, et al.
Publicado: (2020)

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020)

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience
por: Chiron, Raphael, et al.
Publicado: (2022)

Adjunctive inhaled amikacin in infants with ventilator-associated pneumonia optimizes the complex antimicrobial therapy: pilot study
por: Levchenko, Bohdan, et al.
Publicado: (2023)

The ELFE programme and project
por: Laget, J M
Publicado: (1997)

The Nursery Elf (Poetry)
Publicado: (1881)

In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations
por: De Vecchi, Elena, et al.
Publicado: (2008)

NKTR-061 (inhaled amikacin) delivers high lung doses in mechanically ventilated patients with pneumonia and in healthy subjects
por: Eldon, M, et al.
Publicado: (2008)

Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
por: Torres, Antoni, et al.
Publicado: (2018)

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a7lh00tkc2ajsndg38l2fknbui